€10,000 Award for Young Microbiome Researchers
The Pharmabiotics Young Investigator Awards 2018 is a co-initiative between Institut Mérieux and the Pharmabiotic Research Institute in which an award of €10,000 is granted to a young clinician or academic working within the field of Microbiotic Medicinal Products.
LMGE UMR CNRS 6023
Beneficial Bacteria as an Innovative Strategy to Impair Klebsiella Pneumoniae Infections by Modulating the Gut-Lung Axis.
Université Catholique de Louvain
Gut Microbiota as a Therapeutic Target in Cancer Cachexia
King's College London
Faecal Volatile Organic Compounds as Predictors of Response to Dietary Interventions in IBS
Department of Anatomy
University College Cork
Ana Palmeira de Oliveira
Research Centre of
Health Sciences (CICS)
Universidade da Beira Interior
Department of Bioengineering
University of Antwerp
Department of Health
Sciences and Technology
Faculty of Medicine
Pitching Opportunity for Biotechs & Entrepreneurs
showcasing the latest innovations
Presentations followed by Q&A
scientific & business experts
Early stage start-ups, spin-offs, academics and entrepreneurs now have the opportunity to present their innovative microbiome products, services and research to the International Microbiome community within the main Pharmabiotics 2018 conference programme.
Fill in Our Application Form Here.
A skin microbiome company founded in 2015 to commercialize the skin microbiome discoveries of Richard Gallo of UCSD. Our natural beneficial microbes make peptides that kill pathogens like Staph. aureus and even MRSA.
SkinBioTherapeutics plc is harnessing the power of the microbiome to create innovative new therapies for skin in health and disease. Our proprietary technology 'Skinbiotix' is a lysate of a probiotic bacterium with the capacity to enhance the skins barrier, inhibit pathogens and accelerate wound healing. The company is focusing on three applications: a cosmetic, an anti-infective and a treatment for eczema.
Xeno Biosciences is leveraging nascent bariatric surgery microbiome science to develop XEN-101. Based on this science, we have proposed the “air hypothesis” as a mechanism to explain the profound weight loss and the associated microbiome shifts observed after gastric bypass surgery. We created XEN-101, a first-in-class, oral anti-obesity medicine. XEN-101 has preclinical and clinical pilot efficacy data, demonstrating substantial weight loss and corresponding shifts in the gut microbiome. Xeno is currently in early development preparing for Phase I studies.
PharmaBiome is specialized in the isolation, characterization and technology of novel intestinal microbes. Our unique technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures. The scalability of our technology enables an efficient access to new markets addressing the increasing burden of microbiome-related diseases. Using the entire diversity of the gut microbiome, we will deliver the next generation of bio-therapeutics.